
On Tuesday the EMA announced that it had started assessing whether Bavarian Nordic’s smallpox vaccine could be used to combat the ongoing monkeypox outbreak in Europe.
The statement from the EMA mentioned that the authority was waiting for a formal label expansion application for the vaccine, which is called Imvanex in the region.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app